Info

🌱來自：renal-cell-carcinoma

Second-line therapies-of-renal-cell-carcinoma

• Preferred:
  • Cabozantinib,
  • nivolumab,
  • or lenvatinib+everolimus
• Other options:
  • Any listed in 1st line,
    • everolimus,
    • tivozanib,
    • axitinib+avelumab,
    • sorafenib,
    • or bevacizumab

Siblings

• Epidemiology-of-renal-cell-carcinoma
• Histology and molecular biology-of-renal-cell-carcinoma
• Hereditary RCC and germline testing-of-renal-cell-carcinoma
• Clinical presentation-of-renal-cell-carcinoma
• Staging (TNM classification) and prognosis-of-renal-cell-carcinoma
• Treatment principles-of-renal-cell-carcinoma
• Systemic therapy for metastatic clear cell RCC
• Second-line therapies-of-renal-cell-carcinoma
• Combined-modality therapies-of-renal-cell-carcinoma
• Tyrosine kinase inhibitors-of-renal-cell-carcinoma
• Immunotherapies-of-renal-cell-carcinoma
• mTOR inhibitors-of-renal-cell-carcinoma
• Non-clear cell histology-of-renal-cell-carcinoma